Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My guess is that they are unaware that this blog is not Cramer's as well-why not simply call Investor relations and find out if it bothers you?
Facts are the facts. Cramer did not recommend PRWP. The blog is in the source of the misinformation, not PRWP. Anyone who has based a purchase of PRWP upon Cramer's alleged recommendation should reevaluate their position based on the available information.
Everything in your post is strictly your opinion, enjoy. And the CEO's name, as I have mentioned previously, is Theodore D. Zucconi, Ph.D., , not Zucchini. Any future use of the wrong name for the CEO, which seems quite deliberate and derogatory IMO, will result in the deletion of your message. If Ihub does not agree with such a deletion I will be pleased to resign as moderator.
From Vista Partners Updated Research Report:
As we stated in our initiation of coverage we believe DAVANAT® will revolutionize oncology. DAVANAT® has shown in clinical trials that it can increase the uptake of chemotherapeutics into a tumor by 50% and reduce Severe Adverse Events (SAE’s) caused by chemotherapy by up to 50%. Clinical data also indicates DAVANAT® reduces SAE’s for the latest stage patients who would normally suffer numerous SAE’s as a consequence of late stage cancer progression.
The primary chemotherapeutic agents used to treat cancer are Carboplatin & Paclitaxel along with Avastin, Erbitux & 5-Fluorouracil (“5-FU”) which generate billions in revenues annually. These drugs can extend life but they also cause significant side effects. These side effects, which are costly to treat and can become problematic, must be treated in addition to the cancer. Side effects include myelosuppression, mucositis, dermatitis, diarrhea and cardiac toxicity. While these drugs are effective, the duration and size of the dose at which they are administered are limited by their toxicity. For example, 5-FU is a highly effective chemotherapeutic agent when administered in combination with Leucovorin as Leucovorin increases the efficacy of 5-FU. The problem with this dosing regimen, which used to be the standard of care up until a few years ago, is the noticeable side effects such as mucositis and diarrhea. This can be very cumbersome and painful for patients. This is mainly related to the way 5-FU is administered, which is a single dose of drug, usually injected into a vein over a short period of time. After five to ten minutes, 50 percent of 5-FU is already eliminated from the body and results in high plasma concentration and this affects bone marrow function. Patients will experience a drop in white blood cell counts, and this, by itself, affects the repair capacity of patients to repair injuries to mouth mucosa, et cetera.
Download Link to Vista Partners Updated Research Report on Pro Pharma:
http://www.mediafire.com/file/dznzqjqozgj/Vista_Update_PRWP.pdf
you are correct, the blog that has the PRWP recommendation is very misleading and I have removed the reference in the IBox. It doesn't change how I feel about PRWP and the updated Vista Partners research report, which is available at this link, http://www.mediafire.com/file/dznzqjqozgj/Vista_Update_PRWP.pdf, has the best overview of the potential for the company.
Vista, along with a growing list of analysts and advisors, including Jim Cramer, have either visited or spoken with the highly qualified management team organized in the past year, looked at the trial information, and agree with those of us who have bought into the company and its story.
As for the lack of clinical data, why would the former head of the Baylor Medical School, Dr. Peter Traber, who was also the chief regulatory official of GlaxoSmithKline, be involved with company, as he has since February, 2009. It makes no sense to me unless he is convinced that Davanat has great potential.
On February 12, 2009, Peter Traber, M.D., was named a member of the Board of Directors. Dr. Traber is President Emeritus and former Chief Executive Officer of Baylor College of Medicine. Previously, Dr. Traber was Senior Vice President Clinical Development and Regulatory Affairs and Chief Medical Officer of GlaxoSmithKline plc. He has also served as Chief Executive Officer of the University of Pennsylvania Health System, as well as Chair of the Department of Internal Medicine and Chief of Gastroenterology for the University of Pennsylvania School of Medicine
I guess Dr. Traber, among many others, both inside and outside the company, is satisfied that there is clinical merit to Davanat. He hasn't forgotten his involvement and will be present at the Annual Meeting on May 25th. Anyone interested in finding out more can attend the meeting, it is open to all shareholders.
You have to be kidding, it's at the top of his Blog on May 10th with a nice article as well:
http://madmoneyfund.blogspot.com/
PRWP releases Q1 results, reaffirms plans to introduce DAVANAT in Columbia and begin Phase III trial in 2010:
http://finance.yahoo.com/news/ProPharmaceuticals-Reports-bw-1275709864.html?x=0&.v=1
PRWP completes 10X Fund investment, ready to introduce Davanat in South America during 2010:
http://app.quotemedia.com/quotetools/newsStoryPopup.go?storyId=30739183&topic=PRWP&symbology=null&cp=off&webmasterId=89753
I don't even have the heart to make any kind of comment about this stock and how bad it is, I hope those of you who remain with shares have enough intelligence to not throw good money after bad.
Rufus had a major decision to make today, here were his choices:
1. Save the world from shorts, restore CSHD to its rightful place, give all shareholders $15 a share and schedule a moon landing for next Tuesday
OR
2. Muck out a stable and tar a roof.
I guess #2 was more important to maintaining world order.
Better luck next Monday...
First of all, the new CEO's name is Zucconi, but I'm sure you knew that already:
Theodore D. Zucconi, Ph.D., is Chief Executive Officer and President of the Company. Dr. Zucconi is presently a Director of the Company, and President of the Company from October 2007 to December 31, 2008. Formerly, since 2002, Dr. Zucconi was President of Implementation Edge, a management consulting firm that specializes in organizational performance improvement. From 1994 until 2002, Dr. Zucconi served in various capacities at Motorola, including Director of Motorola University. Prior to Motorola, Dr. Zucconi held technical, operational, and scientific positions at various high technology companies. Dr. Zucconi received his Ph.D. in analytical chemistry from State University of New York in 1977. Dr. Zucconi also received a Master’s Certificate in international management from Thunderbird University.
The Executive Chairman is James Czirr:
Mr. James C. Czirr, a Series B director, was appointed a director and became Executive Chairman of the Board of Directors on February 12, 2009. Mr. Czirr is a co-founder 10X Fund, L.P. and is a managing member of 10X Capital Management LLC, the general partner 10X Fund, L.P. Mr. Czirr was a co-founder of Pro-Pharmaceuticals in July 2000. Mr. Czirr was instrumental in the early stage development of Safe Science Inc., a developer of anti-cancer drugs, served from 2005 to 2008 as Chief Executive Officer of Minerva Biotechnologies Corporation, a developer of nano particle bio chips to determine the cause of solid tumors, and was a consultant to Metalline Mining Company Inc. (NYSE Alternext US: MMG), a mineral exploration company seeking to become a low cost producer of zinc. Mr. Czirr received a B.A. degree from the University of Michigan.
The Vice Chairman of the BOD is Rod Martin:
Rod D. Martin, J.D., is a Vice Chairman of the Board of Directors and a member of the Nominating and Corporate Governance Committee and the Compensation Committee. Mr. Martin is co-founder and principal of 10X Capital Management. Mr. Martin previously served as a senior advisor to PayPal, Inc. founder Peter Thiel, most notably during PayPal's IPO and subsequent merger with eBay Inc., and afterward at Clarium Capital, a global macro hedge fund which today has more than $5 billion under management. Mr. Martin also served as Director of Policy Planning & Research for former Arkansas Governor and presidential candidate Mike Huckabee. He is a widely noted author and speaker, and leads several non-profit organizations.
Board Members include the following:
Gilbert F. Amelio, Ph.D.
Member of the Board of Directors
Gilbert F. Amelio, Ph.D., is a named a Director of the Company and a member of the Nominating and Corporate Governance Committee. Dr. Amelio is a venture capitalist focused on early stage companies, is a senior partner of Sienna Ventures and lead director of AT&T, Inc. Dr. Amelio is a former CEO of Apple, Inc., and of National Semiconductor Corporation, which he led from its worst-ever to its best-ever quarter in just three years. Dr. Amelio also has served as a director of Chiron (now a part of Novartis Vaccines and Diagnostics), is the author of two business best-sellers, and has been personally awarded sixteen patents.
Peter Traber, M.D.
Member of the Board of Directors
On February 12, 2009, Peter Traber, M.D., was named a member of the Board of Directors. Dr. Traber is President Emeritus and former Chief Executive Officer of Baylor College of Medicine. Previously, Dr. Traber was Senior Vice President Clinical Development and Regulatory Affairs and Chief Medical Officer of GlaxoSmithKline plc. He has also served as Chief Executive Officer of the University of Pennsylvania Health System, as well as Chair of the Department of Internal Medicine and Chief of Gastroenterology for the University of Pennsylvania School of Medicine.
This seems like a pretty solid management team to me, I guess you have other criteria known only to yourself.
Chief Scientist:
Anatole A. Klyosov, Ph.D., D.Sc.
Chief Scientist
Member of the Scientific Advisory Board
Anatole A. Klyosov, Ph.D., D.Sc., is a founder, our Chief Scientist and a co-inventor of our patented technology. Dr. Klyosov was vice president, research and development for Kadant Composites, Inc., a subsidiary of Kadant, Inc. (KAI-NYSE), where he directed, since 1996, a laboratory performing work in biochemistry, microbiology, polymer engineering, and other fields in the development of composite polymer-based products. From 1990 to 1998, Dr. Klyosov was visiting professor of biochemistry, Center for Biochemical and Biophysical Sciences, Harvard Medical School, and from 1981 to 1990 he was professor and head of the Carbohydrates Research Laboratory at the A.N. Bach Institute of Biochemistry, USSR Academy of Sciences. Dr. Klyosov was elected as a member of the World Academy of Art and Sciences and is the recipient of several distinguished awards including the USSR National Award in Science and Technology. He has published more than 230 peer-reviewed articles in scientific journals, authored books on enzymes, carbohydrates, and biotechnology, and holds more than 20 patents. Dr. Klyosov has consulted for numerous organizations including the World Bank and the United Nations Industrial Development Organization, and serves on the editorial boards of scientific journals in the field of biochemistry and biotechnology. Dr. Klyosov earned his Ph.D. and D.Sc. degrees in physical chemistry, and an M.S. degree in enzyme kinetics, from Moscow State University.
The following is a list of publications of Dr. Anatole A. Klyosov, selected from more than 250 published peer-review articles, review papers, patents, and books.
Klyosov, A.A., Platt, D. Delivery of a Therapeutic Agent in a Formulation for Reduced Toxicity", Application for U.S. Patent, submitted March, 2001.
Keung, W.-M., Klyosov, A.A., Vallee B.L. Daidzin Inhibits Mitochondrial Aldehyde Dehydrogenase and Suppresses Ethanol Intake of Syrian Golden Hamsters. PROC. NATL. ACAD. SCI., 94, 1675-1679, 1997.
Hjelmqvist, L., Lundgren, R., Norin, A., Jornvall, H., Vallee, B., Klyosov, A., Keung, W.M. Class 2 Aldehyde Dehydrogenase. Characterization of the Hamster Enzyme, Sensitive to Daidzin and Conserved Within the Family of Multiple Forms. FEBS LETTERS, 416(1), 99-102, 1997.
Klyosov, A.A., Rashkovetsky, L.G., Tahir, M.K., W.-M. Keung. Possible Role of Liver Cytosolic and Mitochondrial Aldehyde Dehydrogenases in Acetaldehyde Metabolism. BIOCHEMISTRY, 35, 4445-4456, 1996.
Klyosov, A.A. Kinetics and Specificity of Human Liver Aldehyde Dehydrogenases Toward Aliphatic, Aromatic, and Fused Polycyclic Aldehydes. BIOCHEMISTRY, 35, 4457-4467, 1996.
Klyosov, A.A. Industrial Enzyme Engineering. 6-Volume Treatise (1995, Harvard Medical School).
Volume 1. Biomass Conversion With Cellulases
Volume 2. Principles of the Enzymatic Degradation of Cellulose
Volume 3. Economics of Enzymatic Cellulose Hydrolysis
Volume 4. Industrial Production with Immobilized Enzymes: High-Fructose Corn Syrups and Amino Acids for Food and Feed
Volume 5. Industrial Production with Immobilized Enzymes: Antibiotics, Food Additives and Dairy Products
Volume 6. Industrial Production with Immobilized Enzymes: Saccharose and Starch Hydrol
Rashkovetsky, L.G., Maret, W., Klyosov, A.A. Human Liver Aldehyde Dehydrogenases: New Method of Purification of the Major Mitochondrial and Cytosolic Enzymes and Re-Evaluation of Their Kinetic Properties. BIOCHIM. BIOPHYS. ACTA, 1205, 301-307, 1994.
Bolobova, A.V., Zhukov, A.V., Klyosov, A.A. Lipids and Fatty Acids in Cellulosomes of Clostridium thermocellum. APPLIED MICROBIOL. BIOTECHNOL, 42, 128-133, 1994.
Klyosov, A.A. Trends in Biochemistry and Enzymology of Cellulose Degradation. BIOCHEMISTRY, 29, 10577-10585, 1990.
Bolobova, A.V., Klyosov, A.A. Comparison of the Efficiency of the Microcrystalline Cellulose Hydrolysis with Bacterial and Fungal Cellulases. PRIKL. BIOKHIM. MICROBIOL., 26, 321-327, 1990.
Lapidus, A.L., Mochulskii, A.V., Podkovyrov, S.M., Lebedeva, M.I., Antipin, A.A., Izotova, L.S., Zagnitko, O.P., Komolova, G.S., Klyosov, A.A., Veiko, V.P., Mashko, S.V. Expression of the hAng Gene in Escherichia coli; Isolation and Characterization of Human Recombinant Ser-(-1) Angiogenin. BIOMEDICAL SCIENCE, 1, 597-604, 1990.
Sinitsyn, A.P., Mitkevich, O.V., Gusakov, A.V., Klyosov, A.A. Decrease in Reactivity and Change of Physicochemical Parameters of Cellulose in the Course of Enzymatic Hydrolysis. CARBOHYDRATE POLYMERS, 10, 1-14, 1989.
Chernoglazov, V.M., Ermolova, O.V., Vozny, Y.V., Klyosov, A.A. A Method for Detection of Cellulases in Polyacrylamide Gels Using 5-Bromoindoxyl-beta-D- Cellobioside: High Sensitivity and Resolution. ANAL. BIOCHEM., 182, 250-253, 1989.
Chernoglazov, V.M., Jafarova, A.N., Klyosov, A.A. Continuous Photometric Determination of Endo-1,4-Beta-D-Glucanase (Cellulase) Activity Using 4-Methylumbelliferyl-Beta-D-Cellobioside as a Substrate. ANAL. BIOCHEM., 179, 186-189, 1989.
Vlasenko, E.Yu., Papkovskaya, N.Yu., Sinitsyn, A.P., Scherbukhin, V.D., Klyosov, A.A. Hydrolysis of Mannose-Containing Polysaccharides by Endo-1,4-beta-Glycanases. PRIKL. BIOKHIM. MIKROBIOL., 25, 604-613, 1989.
Melnik, M.S., Rabinovich, M.L., Klyosov, A.A. A New Type of Clostridium thermocellum Endoglucanase Produced by the Recombinant Strain of E. coli: Purification and Separation of Multiple Forms. BIOKHIMIYA, 54, 284-291, 1989.
Melnik, M.S., Kapkov, D.V., Mogutov, M.A., Rabinovich, M.L., Klyosov, A.A. A New Type of Clostridium thermocellum Endoglucanase Produced by the Recombinant Strain of E. coli: Some Properties and Identification in Donor Cells. BIOKHIMIYA, 54, 387-396, 1989.
Klyosov, A.A. Enzyme Engineering at the Industrial Level. UNIDO Study, Separate Edition, 1989, 108 p.
Klyosov, A.A. Cellulases of the Third Generation. In: "Bioprocess Engineering. The First Generation". Ellis Horwood Limited, Chichester, England, 1989, p. 59-67.
Klyosov, A.A. Which Problems of Modern Biochemistry and Enzymology Seem to be the Most Important and Interesting. Z. KHIM. OBS. im. D.I.Mendeleeva, 1989, No.1, p. 90-105.
Klyosov, A.A. Angiogenin, a Protein Factor of Angiogenesis of Human Tumor Cells. USPEKHI SOVR. BIOL. (Advances of the Modern Biology), 196, 264-278, 1988.
Klyosov, A.A. Angiogenin, a Protein Inducing a Blood Supply to Tumor Cells. In:"Science and Technology News", Ser. "Biotechnologia", No.1, VINITI PRESS, 1988, p.7-29.
Klyosov, A.A. Cellulases of the Third Generation. In: BIOCHEMISTRY AND GENETICS OF CELLULOSE DEGRADATION. Academic Press, London, 87-99, 1988.
Klyosov, A.A., Ermolova, O.V., Chernoglazov, V.M. A Thermostable Endo-1,4-beta- Glucanase from Myceliophthora thermophila. BIOTECHNOL. LETTERS, 10, 351-354, 1988.
Chernoglazov, V.M., Ermolova, O.V., Klyosov, A.A. Adsorption of High-Purity Endo-1,4-beta-Glucanases from Trichoderma reesei on Components of Lignocellulosic Materials: Cellulose, Lignin, and Xylan. ENZYME MICROB. TECHNOL., 10, 503-507, 1988.
Sinitsyn, A.P., Klyosov, A.A., Rabinovich, M.L., Gusakov, A.V., Morozov, A.M. Biotechnology of the Enzymatic Conversion of Cellulose.VINITI PRESS, Moscow,1988, 153 p.
Skryabin, G.K., Golovlev, E.L., Klyosov, A.A., eds. Microbiology and Biochemistry of Degradation of Plant Materials, NAUKA, Moscow, 1988, 320 p.
Klyosov, A.A., ed. Lectines in Studying Proteins and Carbohydrates. VINITI PRESS, Moscow, 1987, 288 p.
Berezin, I.V., Klyosov, A.A., et al. Enzyme Engineering. VYSHAYA SHKOLA, Moscow, 1987, 143 p.
Kovalev, G.V., Sinitsyn, A.P., Volf, E.G., Kalyazin, E.P., Bugaenko, L.T., Klyosov, A.A. Enzymatic Conversion of Irradiated Cellulosis Materials. BRITISH POLYMER J., 19, 63-66, 1987.
Gusakov, A.V., Sinitsyn, A.P., Klyosov, A.A. Factors Affecting the Enzymatic Hydrolysis of Cellulose in Batch and Continuous Reactors: Computer Simulation and Experiment. BIOTECHNOL. BIOENG., 29, 906-910, 1987.
Gusakov, A.V., Sinitsyn, A.P., Klyosov, A.A. A Theoretical Comparison of the Reactors for the Enzymatic Hydrolysis of Cellulose. BIOTECHNOL. BIOENG., 29, 898-900, 1987.
Klyosov, A.A. On the Three Unsolved Fundamental Problems of Enzymatic Production of Sugars from Plant Materials. BIOTECHNOLOGIA, 3, 549-552, 1987.
Klyosov, A.A., Mitkevich, O.V., Sinitsyn, A.P. Role of the Activity and Adsorption of Cellulases in the Efficiency of the Enzymatic Hydrolysis of Amorphous and Crystalline Cellulose. BIOCHEMISTRY, 25, 540-542, 1986.
Skryabin, G.K., Golovlev, E.L., Klyosov, A.A., eds. Bioconversion of Plant Materials, NAUKA, Moscow, 1986, 296 p.
Rabinovich, M.L., Klyosov, A.A., Melnick, M.S. The Titration of the Active Centres of Cellobiohydrolase from Trichoderma reesei. ANAL. BIOCHEM., 156, 489-494, 1986.
Klyosov, A.A. Enzymatic Conversion of Cellulosic Materials to Sugar and Alcohol. The Technology and its Implications. APPL. BIOCHEM. BIOTECHNOL., 12, 249-300, 1986.
Klyosov, A.A. Enzymatic Catalysis. Vol.2. Enzymatic Degradation of Polymers. MOSCOW UNIVERSITY PRESS, Moscow, 1984, 214 p.
Klyosov, A.A. Industrial Processes Using Immobilized Enzymes. In:"Introduction to Applied Enzymology", MOSCOW UNIVERSITY PRESS, Moscow, 1982, p.353-379.
Berezin, I.V., Kalunyanz, K.A., Rabinovich, M.L., Klyosov, A.A. et al. Apparatus for the Hydrolysis of Polysaccharide Materials. SU Patent No. 962310, Nov.27,1980/June 1, 1982.
Rabinovich, M.L., Klyosov, A.A., Berezin, I.V., Myagkih, I.V., Martianov, V.A. Purification of Cellulases. SU Patent No. 975796, March 31,1981/July 21,1982.
Berezin, I.V., Kalunyanz, K.A., Rabinovich, M.L., Klyosov, A.A. et al. Preparation of Sugars from Cellulose-Containing Plant Materials. SU Patent No. 949002. Nov.27,1980/July 14, 1981.
Rabinovich, M.L., Klyosov, A.A., Berezin, I.V. Pretreatment of Polysaccharide Material for a Subsequent Hydrolysis. SU Patent No. 948145. Dec.26,1980/Aug.25,1981.
Klyosov, A.A., Rabinovich, M.L. Enzymatic Conversion of Cellulose to Glucose: Present State of the Art and Potential. In:"Enzyme Engineering: Future Directions", PLENUM PRESS, New York, 1980, p. 83-165.
Wingard, L/B., Berezin, I.V., Klyosov, A.A., eds. Enzyme Engineering - Future Directions, PLENUM PRESS, New York, 1980, 521 p.
Klyosov, A.A., Berezin, I.V. Enzymatic Catalysis.Vol.1. Specificity of Enzyme Catalysis. MOSCOW UNIVERSITY PRESS, Moscow, 1980, 264 p.
Klyosov, A.A., Gerasimas, V.B., Sinitsyn, A.P. Substrates Stabilization of Soluble and Immobilized Glucoamylase Against Heating. In: ENZYME ENGINEERING - FUTURE DIRECTIONS (L.B.Wingard, I.V.Berezin, A.A.Klyosov, eds), PLENUM PRESS, New York, 197-215, 1980.
Wingard, L.B., Klyosov, A.A. Some Thoughts of the Future of Enzyme Engineering. In: ENZYME ENGINEERING - FUTURE DIRECTIONS (L.B.Wingard, I.V.Berezin, A.A.Klyosov, eds), PLENUM PRESS, New York, 499-506, 1980.
Klyosov, A.A., Sinitsyn, A.P., Rabinovich, M.L. The Comparative Role of Exoglucosidase and Cellobiase in Glucose Formation from Cellulose. In: ENZYME ENGINEERING, v.5 (H.H.Weetall, G.P.Royer, eds), PLENUM PRESS, New York, 153-165, 1980.
Berezin, I.V., Klyosov, A.A., Martinek, K. General Principles of Enzymatic Catalysis. In: "Chemistry Reviews (Soviet Scientific Reviews)", 1979, Section B, vol.1, 205-277.
Klyosov, A.A., Gerasimas, V.B. The Thermostability of Glucoamylase Immobilized in Different Ways Has a Certain Limit. BIOCHIM.BIOPHYS.ACTA, 571, 162-165, 1979.
Klyosov, A.A. Specificity of Enzyme Catalysis. In:"Advances in Bioorganic Catalysis", MOSCOW UNIVERSITY PRESS, Moscow, 1979, p.7-56.
Berezin, I.V., Klyosov, A.A. The Practical Course of Chemical and Enzyme Kinetics. MOSCOW UNIVERSITY PRESS, Moscow, 1976, 326 p.
Berezin, I.V., Klyosov, A.A., Rabinovich, M.L. Kinetics of Enzymatic Reactions in Heterogeneous Systems. I. The Kinetic Regularities for the Bacterial Cell Micrococcus lysodeikticus Degradation by Lysozyme. BIOORGAN. KHIMIYA, 2, 680-688, 1976.
Rabinovich, M.L., Klyosov, A.A., Berezin, I.V. Kinetics of Enzymatic Reactions in Heterogeneous Systems. II. Bacteriolytic Action of Lysozyme on Micrococcus lysodeikticus Cells. BIOORGAN. KHIMIYA, 2, 689-699, 1976.
Svedas, V.K., Klyosov, A.A., Nys, P.S., Savitskaya, E.M., Berezin, I.V. Studies on Penicillin Amidase from E. coli. Kinetics of the Enzymatic Hydrolysis of 7-Phenylacetamidodeacetoxycephalosporanic Acid. ANTIBIOTIKI, 21, 698-704, 1976
Johansen, J.T., Klyosov, A.A., Vallee, B.L. Circular Dichroism - Inhibitor Titrations of Arsanilazotyrozine-248 Carboxypeptidase A. BIOCHEMISTRY, 15, 296-303, 1976.
Berezin, I.V., Klibanov, A.M., Klyosov, A.A., Martinek, K., Svedas, V.K. The Effect of Ultrasound as a New Method of Studying Conformational Transitions in Enzyme Active Sites. pH- and Temperature-Induced Conformational Transitions in the Active Center of Penicillin Amidase. FEBS LETTERS, 49, 325-328, 1975.
Klyosov, A.A., Nguen Van Viet, Berezin, I.V. The Reactions of Chymotrypsin and Related Proteins with Ester Substrates in Non-Aqueous Solvents. EUR. J. BIOCHEM., 59, 3-7, 1975.
The Ibox is updated as of May 7,2010.
Jim Cramer (Adam Feuerstein's boss at TheStreet.com) adds PRWP to his buy list. I guess he and Adam have radically different opinions.
how about all the people who lost their shirts trusting the SEC filings of a scam artist, lying hustler who now want to see him spend the rest of his life in jail? Do you think they might have an interest in this? As for shorts, how in the world can they still be short when the stock has been REVOKED?
Talk about delusional...
sorry, duplicate post (browser error)
One more thing-the Ibox relates to David Platt, the former CEO, who was replaced in Feb, 2009. If you want someone to blame for all the bad financing, lack of progress, and other events that drove this company back for a long time, that is who to blame. The current management team have been righting the past wrongs since the changes and are now ready to move this company forward.
All of these old posts relate to a management team that was replaced over a year ago. Maybe it's time for some of you to actually look at the developments since that time instead of repeating the 'same old, same old'. I've done enough due diligence to be convinced this company is for real and Davanat is the only drug, when used in conjunction with widely used chemo treatments such as 5-FU, that will significantly reduce Serious Side Effects such as mucositis while, at the same time, enhancing the effectiveness of the chemotherapy treatment-their studies to date indicate that 50% more of the chemo drug gets into the tumor and it stays 50% longer.
I'm not a pumper and bought in about 6 months ago and am pleased with the progress since then. Time will tell who is right and who is wrong.
I feel bad for you guys, actually. You bought into some hype and had no idea of the track record of the management team. All it did today was retrace the loss of yesterday and it's down over 90% from the point of the reverse split. Your board mod, who pumped this stock to the point of being ridiculous for 2 years, has left the board completely, finally admitting he was wrong. I hope you get your money back but the reality is there will eventually be more dilution and probably another reverse split, you just can't bootstrap an oil & gas exploration company with little or no expansion money, that's why the successful companies in this space are the ones like Exxon and Chevron.
you can never go wrong betting against anything Billy Robinson tries, this company will be no different.
I'll explain this all, very simply:
Paez is a scam artist who contacted Sabra, another scam artist, with forged bonds.
Sabra found Rufus through mutual connections, she got him connected with Alexander.
The Venezuelan scam artists threatened Sabra because of all the publicity around the company, she pulled the forged bonds.
Rufus tried to scam the stock market, it didn't work. And now he'll most likely go to jail, unfortunately, without some of othe others who should also be serving time.
Does that make it clear?
The way I look at it, Robinson claimed they are currently doing about a million per month in revenue.
12 million / 78 million = .154 per share based on current earnings.
You need to subtract expenses from revenue to get earnings, I doubt they are netting more than 10% right now and it's probably lower. But even at 30% net profit, using your math, this is a 5 cent stock at best with no further dilution-and that is really stretching it since Oil and Gas exploration and development is a capital intensive business.
And, there are still 125M shares authorized, what makes you think there aren't warrants and other derivatives already issued that aren't accounted for in the OS that will provide further dilution?
Not burned but know people who were. Just look back at all the different versions of this company and how many times there have been empty promises-Cyber Defense, Techsphere, Proxity Electronics, Proxity Financial, now CAVU. Do you know how many reverse splits have there been?
He was ready to do a proposed reverse merger with a 80:1 dilution for his shareholders, did you know that (the merger wasn't completed because the other CEO was as pathetic as he is)? Now he's done another 250:1 reverse merger, screwed over his earlier shareholders, and now the new ones like you are being screwed over again-the stock was 15 cents after the merger and as high as 44 cents, now it's 1.7 cents in spite of NO bad news. And you attribute that to shorters? If there are shorters, it's because there's been some PIPE financing that wasn't announced and the PIPE investors are shorting to drive the stock down to pick up millions more shares, just do some research about this kind of financing because it's all over the pink sheets. In order for it to work, though, the company has to cooperate by putting out tons of bs press that sounds good and has no basis.
'Billy' has been saying bs like this for years about a variety of businesses, enjoy being the latest ones to get pulled in.
No one is shorting this stock, least of all me or anyone I know. I posted on this board in October, after the reverse merger, that the stock would go back to the pre-split price because that was the plan. I was right, bye, bye...
the easiest way to go broke is to believe 'Billy' at his word, just look at his track record.
You've been 'Billied' once again, that's all you need to know. Put out a bs Press release, run the stock up a little, let some private placement guys get out, wash, rinse, repeat.
How does it look at half that price a day later?
You guys have just been 'Billied' again with false hope.
I'm guessing the Exhibits aren't suitable for public consumption, particularly if you've eaten in the past week.
more like 5 vs. 0 considering the delusion exhibited about Dufus over the past 4 years.
more than the Summary Judgment filing?
He's only interested in the laws for the Moon, that's where he thinks Dufus is taking his flock... Besides, he's had his own run ins with the law:
http://law.du.edu/documents/student-law-office-clinical-programs/Krystofik-SJ-Decision.pdf
No response, Summary Judgment:
CONCLUSION
WHEREFORE, Plaintiff Inger Christine Krystofik’s Motion for Summary Judgment is GRANTED because there remain no genuine issues of material fact and Krystofik is entitled to judgment on all claims as a matter of law. Plaintiff’s counsel has 10
days from the date of this Order to file a Notice to Set Hearing on Damages and contact this Court’s clerk’s office to obtain dates for a damages hearing.
Very consistent with each legal runin with Dufus, it's always someone else's fault, I did nothing.
Anyone who believes that the 'shorts' are driving this down and that this is a buying opportunity deserves what they get. It's the company that continuously dilutes the stock to raise money, not any outside source.
You got it, but you've known that for a long time...
Wow!!!!!!
73,840 short shares x 0.011= $745 short
That is a huge sum for a stock to overcome, I'm sure that's why it's dropped from 30 cents to 1 cent with no negative news and 17 positive press releases.
Posted by: rrufff Date: Thursday, April 02, 2009 9:49:44 AM
In reply to: youngvet who wrote msg# 867 Post # of 2552
Here's the news. Note that the minority interest is not spelled out so how useful is it? The overall picture could work out and I hope it does, but current shareholders are getting shafted with the 1/250 reverse split.
Note also the preferreds and the potential dilution. No mention is made of debt that could dilute or other elements of the proposed capital structure.
But, the most important part of this filing is the increase in authorized shares to 600 million. Now, why would they need to do this given they are reducing the outstanding share count by a massive reverse split?? The answer is that the dilution will not stop unfortunately.
Caveat Emptor
GhostRiderX
GhostRiderX 1
Investment Philosophy: Play the penny flippers with low floats get in get out get gone! ....Next!
Quote: Find a penny pick it up, flip it quick before you're stuck!!
Posted by: GhostRiderX
Date: Monday, December 07, 2009 3:42:37 PM
In reply to: mickymoose99 who wrote msg# 1487
Post # of 2547
No doubt CAVR will run high...Very High!!!
Posted by: GhostRiderX
Date: Tuesday, December 08, 2009 6:01:29 AM
In reply to: cyclone101 who wrote msg# 1492
Post # of 2547
$1.00 coming soon... is my prediction!!!
Then it will continue to trend up!!!
Posted by: GhostRiderX
Date: Wednesday, November 25, 2009 6:23:39 PM
In reply to: Rawnoc who wrote msg# 1354
Post # of 2547
I Know $1.00 is on the way!!!!
Posted by: GhostRiderX
Date: Saturday, November 21, 2009 12:52:31 PM
In reply to: cyclone101 who wrote msg# 1293
Post # of 2547
I must be upfront and say the $5.00 target is the high end for near term.
The actual prediction is $3.00-$5.00 near term.
Still can't complain about that!!!
Posted by: GhostRiderX
Date: Wednesday, November 18, 2009 7:13:18 PM
In reply to: Rawnoc who wrote msg# 1215
Post # of 2547
I say YES! ...Above $1.00 for sure!!!
You have a great track record on this stock, maybe you should try something else:
Posted by: cashflow429 Date: Monday, February 08, 2010 12:36:11 PM
In reply to: None Post # of 2543
CAVR looking awesome .06's are up , we might see .10 today ?